Scroll down for safety information
Although some patients lived longer and some patients did not live as long, patients with advanced liposarcoma who were treated with HALAVEN in a clinical trial lived an average of 15.6 months compared with patients treated with other chemotherapy, who lived an average of 8.4 months.
Learn about the science behind how HALAVEN works
Find out if you are eligible for financial support
*Eligible commercially insured patients may pay as little as $0 per month, with an annual limit of $18,000